Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,707 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,707 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Enrollment posture brief
Registry condition prostate-cancer
OPEN 275 | RECR 37% | LATE 75 | EARLY 344 | RANK #4 | SPON 53
Volume-matched condition peers
Nearest open-share peer: Chronic Disease (37% recruiting · 49 trials)
Prostate Cancer lists 275 open slots (37% of 749 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 13 of 15
Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
Christopher Sweeney, MBBS
NCT00216099
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
University of California, San Francisco
NCT00309894
A Study of Imatinib and Docetaxel in Prostate Cancer
Leonard Appleman
NCT00251225
Smart Prostate Specific Antigen (PSA) Screening Study
University of Illinois at Chicago
NCT04782713
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Astex Pharmaceuticals
NCT01685268
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
Dana-Farber Cancer Institute
NCT00134654
Saw Palmetto: Symptom Management for Men During Radiation Therapy
Michigan State University
NCT01585246
Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy
University of California, San Francisco
NCT05324098
Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer
Weill Medical College of Cornell University
NCT00195039
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
University of Maryland, Baltimore
NCT00005028
Effects of Sulforaphane on Normal Prostate Tissue
Fred Hutchinson Cancer Center
NCT00946309
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer
University of Maryland, Baltimore
NCT00003400
Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02225925
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Cancer Institute (NCI)
NCT00924027
A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality
University of Colorado, Denver
NCT04565457
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
Polaris Group
NCT01497925
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
NCT02366494
Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT01542021
Phase 1 of EC1169 In Patients With Recurrent MCRPC
Endocyte
NCT02202447
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Duke University
NCT02457715
Study of Individualized Amonafide to Treat Prostate Cancer
Xanthus Pharmaceuticals
NCT00087854
Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
Alliance for Clinical Trials in Oncology
NCT00005810
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
National Cancer Institute (NCI)
NCT03315871
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
National Cancer Institute (NCI)
NCT02430480
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Bristol-Myers Squibb
NCT00441337
Staying Strong and Healthy During Androgen Deprivation Therapy (ADT) for Men
University of Kansas Medical Center
NCT02969577
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Duke University
NCT02057939
PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
Indiana University
NCT03429244
SBRT for Organ Confined Prostate Cancer
Northwell Health
NCT02653248
White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy
City of Hope Medical Center
NCT00779168
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients
Saladax Biomedical
NCT02376296
Questionnaire and Fall Risk Assessment
M.D. Anderson Cancer Center
NCT00836238
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
Synta Pharmaceuticals
NCT00808418
Impact of Acetazolamide in Reducing Referred Postoperative Pain
Medical College of Wisconsin
NCT04470843
Phase I Trial of 225Ac-J591 in Patients With mCRPC
Weill Medical College of Cornell University
NCT03276572
Prostate Biomarker Study
Memorial Sloan Kettering Cancer Center
NCT00574899
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02601014
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Robert Dreicer MD
NCT00939510
Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate
Timothy Showalter, MD
NCT01868386
Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer
University of California, San Francisco
NCT01229618
Comprehensive Lifestyle Improvement Program for Men With Prostate Cancer
University of Arizona
NCT04000464
Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
Steba Biotech S.A.
NCT00946881
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
OncoNano Medicine
NCT03735680
Testosterone Therapy in Castration Resistant Prostate Cancer
University of Colorado, Denver
NCT03734653
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Weill Medical College of Cornell University
NCT00003391
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
Five Eleven Pharma
NCT03073395
Impact of Yoga As Complementary Therapy in Patients Undergoing Radical Prostatectomy
The University of Texas Health Science Center at San Antonio
NCT02620033
MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer
Weill Medical College of Cornell University
NCT03664193
Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors
University of Michigan Rogel Cancer Center
NCT04827459
Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
Oncology Specialists, S.C.
NCT00272038
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer page
749 registered trials, 275 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 275 Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer condition card totals 749 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.